These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 32226429)

  • 1. Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations.
    Hansen UK; Ramskov S; Bjerregaard AM; Borch A; Andersen R; Draghi A; Donia M; Bentzen AK; Marquard AM; Szallasi Z; Eklund AC; Svane IM; Hadrup SR
    Front Immunol; 2020; 11():373. PubMed ID: 32226429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
    Turajlic S; Litchfield K; Xu H; Rosenthal R; McGranahan N; Reading JL; Wong YNS; Rowan A; Kanu N; Al Bakir M; Chambers T; Salgado R; Savas P; Loi S; Birkbak NJ; Sansregret L; Gore M; Larkin J; Quezada SA; Swanton C
    Lancet Oncol; 2017 Aug; 18(8):1009-1021. PubMed ID: 28694034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
    de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
    Front Immunol; 2021; 12():592031. PubMed ID: 34335558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display.
    Wickström SL; Lövgren T; Volkmar M; Reinhold B; Duke-Cohan JS; Hartmann L; Rebmann J; Mueller A; Melief J; Maas R; Ligtenberg M; Hansson J; Offringa R; Seliger B; Poschke I; Reinherz EL; Kiessling R
    Front Immunol; 2019; 10():2766. PubMed ID: 31921104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy.
    Xia J; Bai P; Fan W; Li Q; Li Y; Wang D; Yin L; Zhou Y
    Front Immunol; 2021; 12():644637. PubMed ID: 33927717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell Responses to
    Deniger DC; Pasetto A; Robbins PF; Gartner JJ; Prickett TD; Paria BC; Malekzadeh P; Jia L; Yossef R; Langhan MM; Wunderlich JR; Danforth DN; Somerville RPT; Rosenberg SA
    Clin Cancer Res; 2018 Nov; 24(22):5562-5573. PubMed ID: 29853601
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal Cell Carcinoma-Infiltrating CD3
    Lee HW; Park C; Joung JG; Kang M; Chung YS; Oh WJ; Yeom SY; Park WY; Kim TJ; Seo SI
    Curr Issues Mol Biol; 2021 May; 43(1):226-239. PubMed ID: 34071865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ.
    Ronsin C; Chung-Scott V; Poullion I; Aknouche N; Gaudin C; Triebel F
    J Immunol; 1999 Jul; 163(1):483-90. PubMed ID: 10384152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neoepitope landscape of breast cancer: implications for immunotherapy.
    Narang P; Chen M; Sharma AA; Anderson KS; Wilson MA
    BMC Cancer; 2019 Mar; 19(1):200. PubMed ID: 30832597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer.
    Dao T; Klatt MG; Korontsvit T; Mun SS; Guzman S; Mattar M; Zivanovic O; Kyi CK; Socci ND; O'Cearbhaill RE; Scheinberg DA
    Cancer Immunol Immunother; 2021 May; 70(5):1189-1202. PubMed ID: 33123756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.
    Tykodi SS; Fujii N; Vigneron N; Lu SM; Mito JK; Miranda MX; Chou J; Voong LN; Thompson JA; Sandmaier BM; Cresswell P; Van den Eynde B; Riddell SR; Warren EH
    Clin Cancer Res; 2008 Aug; 14(16):5260-9. PubMed ID: 18698046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-level distribution and putative immunogenicity of cancer neoepitopes.
    Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
    BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy.
    Reimann H; Nguyen A; Sanborn JZ; Vaske CJ; Benz SC; Niazi K; Rabizadeh S; Spilman P; Mackensen A; Ruebner M; Hein A; Beckmann MW; van der Meijden ED; Bausenwein J; Kretschmann S; Griffioen M; Schlom J; Gulley JL; Lee KL; Hamilton DH; Soon-Shiong P; Fasching PA; Kremer AN
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.
    Tassi E; Facchinetti V; Seresini S; Borri A; Dell'antonio G; Garavaglia C; Casorati G; Protti MP
    Clin Cancer Res; 2006 Aug; 12(16):4949-57. PubMed ID: 16914584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.
    Schwitalle Y; Linnebacher M; Ripberger E; Gebert J; von Knebel Doeberitz M
    Cancer Immun; 2004 Nov; 4():14. PubMed ID: 15563124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
    Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
    Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
    Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
    Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunization with short peptide particles reveals a functional CD8
    He X; Zhou S; Dolan M; Shi Y; Wang J; Quinn B; Jahagirdar D; Huang WC; Tsuji M; Pili R; Ito F; Ortega J; Abrams SI; Ebos JML; Lovell JF
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34862254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.